TECH Stock Analysis: Buy, Sell, or Hold?
TECH - Bio-Techne Corp.
$51.82
0.86 (1.70%)
▲
5d:
-0.36%
30d:
-12.18%
90d:
-12.5%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When TECH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TECH trading at deep discount. Market pricing in -5.9% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: TECH trading at deep discount. Market pricing in -5.9% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$75.63
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$46.96
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TECH is currently trading at $51.81, which is considered oversold relative to its 30-day fair value range of $51.44 to $57.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.4) compared to its historical average (28.2). Remarkably, the market is currently pricing in an annual earnings decline of 5.9% over the next few years. This pessimistic expectation contrasts with the company's recent 9.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TECH is in a strong uptrend. Immediate support is located at $48.25, while resistance sits at $53.63.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $74.91 (+47.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TECH is in a strong uptrend. Immediate support is located at $48.25, while resistance sits at $53.63.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $74.91 (+47.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$51.44 -
$57.62
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.0% below Wall St target ($74.91)
Fair Price Analysis
30-Day Fair Range
$51.44 -
$57.62
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$48.25
Resistance Level
$53.63
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.44
Wall Street Target
$74.91
(+47.0%)
Revenue Growth (YoY)
-0.4%
Earnings Growth (YoY)
9.1%
Profit Margin
6.7%
Valuation Discount vs History
-5.9% cheaper
PE vs Historical
23.4 vs 28.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.9%
(market-implied from PE analysis)
1-Year Target
$47.94
(-6%)
2-Year Target
$45.12
(-12%)
3-Year Target
$42.45
(-17%)
3-Yr Target (if PE normalizes)
(PE: 23→28)
$51.08
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.4, Growth: 9.7%)
$67.24
(+32%)
Base:
(SPY PE: 22.4, Growth: 9.7%)
$64.27
(+26%)
Bear:
(PE: 19.0, Growth: 9.7%)
$54.63
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Forward PE: 24.21 | Forward EPS (Implied): $2.15
Bull Case
$62.79
(+21%)
Analyst growth 15.0%, PE expands to 25.4
Base Case
$52.00
(0%)
Market implied 0.0%, PE stable at 24.2
Bear Case
$39.78
(-24%)
Severe decline -15.0%, PE contracts to 21.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.4 to 28.2
Stabilization Target:
$61.31
(+20.3%)
PE Expansion Potential:
+20.3%
Share & Embed Analysis
Last updated: March 30, 2026 10:10 AM ET
Data refreshes hourly during market hours. Next update: 11:10 AM
Data refreshes hourly during market hours. Next update: 11:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECH showing a specific setup today?
Insider Activity (6 Months)
4
Buys
2
Sells
+
Net
NEUTRAL
Recent Transactions
April McClain Delaney
SELL
2026-02-24
Ro Khanna
BUY
2026-01-29
April McClain Delaney
SELL
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$47 | 62 BUY |
